Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nat Immunol. 2019 Mar;20(3):326-336. doi: 10.1038/s41590-019-0312-6. Epub 2019 Feb 18.
T cell dysfunction is a hallmark of many cancers, but the basis for T cell dysfunction and the mechanisms by which antibody blockade of the inhibitory receptor PD-1 (anti-PD-1) reinvigorates T cells are not fully understood. Here we show that such therapy acts on a specific subpopulation of exhausted CD8 tumor-infiltrating lymphocytes (TILs). Dysfunctional CD8 TILs possess canonical epigenetic and transcriptional features of exhaustion that mirror those seen in chronic viral infection. Exhausted CD8 TILs include a subpopulation of 'progenitor exhausted' cells that retain polyfunctionality, persist long term and differentiate into 'terminally exhausted' TILs. Consequently, progenitor exhausted CD8 TILs are better able to control tumor growth than are terminally exhausted T cells. Progenitor exhausted TILs can respond to anti-PD-1 therapy, but terminally exhausted TILs cannot. Patients with melanoma who have a higher percentage of progenitor exhausted cells experience a longer duration of response to checkpoint-blockade therapy. Thus, approaches to expand the population of progenitor exhausted CD8 T cells might be an important component of improving the response to checkpoint blockade.
T 细胞功能障碍是许多癌症的标志,但 T 细胞功能障碍的基础以及抗体阻断抑制性受体 PD-1(抗 PD-1)如何重新激活 T 细胞的机制尚不完全清楚。在这里,我们表明,这种治疗作用于耗尽的 CD8 肿瘤浸润淋巴细胞(TIL)的一个特定亚群。功能失调的 CD8 TIL 具有衰竭的典型表观遗传和转录特征,与慢性病毒感染中观察到的特征相似。耗尽的 CD8 TIL 包括一个“祖细胞衰竭”细胞的亚群,它们保持多功能性,长期存在并分化为“终末衰竭”的 TIL。因此,祖细胞衰竭的 CD8 TIL 比终末衰竭的 T 细胞更能控制肿瘤生长。祖细胞衰竭的 TIL 可以对抗 PD-1 治疗作出反应,但终末衰竭的 TIL 则不能。患有黑色素瘤的患者,其祖细胞衰竭细胞的比例较高,对检查点阻断治疗的反应持续时间较长。因此,扩大祖细胞衰竭 CD8 T 细胞群体的方法可能是提高检查点阻断反应的一个重要组成部分。